[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Epidermolysis Bullosa pipeline Research Monitor, 2020- Drugs, Companies, Clinical Trials, R&D pipeline updates, status and outlook

July 2020 | 156 pages | ID: EBCF1C1519CAEN
VPAResearch

US$ 1,599.00

E-mail Delivery (PDF)

Download PDF Leaflet

Wire Transfer
Checkout Later
Need Help? Ask a Question
2020 Epidermolysis Bullosa PIPELINE HIGHLIGHTS
Epidermolysis Bullosa is one of the widely researched conditions during 2020 with 33 companies actively focusing on realizing pipeline’s potential. Development of Epidermolysis Bullosa medicines is identified as integral to the strategy of the majority of companies operating in the industry.
Global Epidermolysis Bullosa market presents promising new product pipeline with NME Projects, pivotal trials, and rapidly phase-advancing therapeutic candidates. Increasing number of companies are assessing the feasibility of developing treatment options for Epidermolysis Bullosa.

Good progress is anticipated during 2020 and 2021 with Epidermolysis Bullosa pipeline molecules advancing from pre-clinical investigation to completion of advanced Phase clinical trials. Epidermolysis Bullosa pipeline continues to expand and progress with novel mechanisms and diverse routes of administration being tested by companies.
Epidermolysis Bullosa DRUG DEVELOPMENT PIPELINE OVERVIEW
The “Epidermolysis Bullosa pipeline Research Monitor, 2020” report is an analytical research study on the progress achieved by pipeline companies during the year along with its historical development, current status, and outlook.
This Epidermolysis Bullosa pipeline review explores high-potential early to late-stage pipeline projects with a continued focus on new insights, accelerated processes, and pipeline progression.

The competitive intelligence report on Epidermolysis Bullosa presents detailed insights into therapeutic drug pipeline development, industry news, deals, and analysis across the length and breadth of the Epidermolysis Bullosa pipeline. Information on R&D pipeline updates, results of key clinical trials are also included in the report.
Epidermolysis Bullosa DRUG PROFILES
Epidermolysis Bullosa development pipeline including projects in early- and late-stage development are detailed in the report. Details of clinical trial data and submissions to regulatory authorities are also provided. For the drug candidates included in the report, the following information is provided-
  • Current Status of Development including phase advancements, regulatory approvals of phases, acquisitions, licensing and technology transfers, product launches in various markets, and others.
  • Phase of development
  • Mechanism of Action
  • Route of Administration
  • Companies involved including originator, licensing companies, developer, investors, and others
  • New molecular entity details
  • Orphan drug designation and other special status provided by regulators
Epidermolysis Bullosa COMPANY PROFILES

Both small size and large size pharmaceutical companies are investing their resources in Epidermolysis Bullosa drug development operations. Further, financial institutions are extending support to small pharmaceutical companies, universities, and other researchers for the development of treatment of Epidermolysis Bullosa. Partnerships and acquisitions are also increasingly observed in the pipeline.

This research report presents an analysis of 33 Epidermolysis Bullosa companies including company overview, key snapshot, contact information, and their strategies on accelerating Epidermolysis Bullosa pipeline development. Mid-stage and early portfolios of these companies are analyzed in detail in the report.

Companies analyzed in the report include- Abeona Therapeutics Inc, Aegle Therapeutics Corp, Almirall SA, Amryt Pharma plc, Anterogen Co Ltd, APR Applied Pharma Research SA, Berg Pharma LLC, BridgeBio Inc, Castle Creek Biosciences Inc, Celularity Inc, Constant Pharmaceuticals LLC , CSA Biotechnologies LLC, CSL Ltd, FIBRX Derm Inc, Holostem Terapie Avanzate Srl, Immusoft Corp, InMed Pharmaceuticals Inc , Krystal Biotech Inc, LambdaGen Therapeutics, Life Sciences Institute Inc, Mesoblast Ltd , OTR3 SAS, Palvella Therapeutics LLC , Phoenix Tissue Repair Inc, Quoin Pharmaceuticals Ltd, RegeneRx Biopharmaceuticals Inc, RHEACELL GmbH & Co KG, Shionogi & Co Ltd, StemRIM Inc, Tetra Bio Pharma, TWi Biotechnology Inc, Wings Therapeutics, Zikani Therapeutics

REASONS TO BUY
  • The current market conditions are forcing companies and investors worldwide to prioritize their investments and accelerate pipeline candidates only through careful quantitative assessment.
  • This research work assists decision makers in pharmaceutical companies towards successful pipeline development through critically evaluated pipeline data
  • Buyers can identify most promising drug candidates for treatment of Epidermolysis Bullosa
  • It allows users to strengthen their pipeline through acquisitions, licensing and collaborations
  • Users can estimate possible delays in the delivery of pipeline or launch of new products
  • Stay ahead of competition through understanding their pipeline progression, strategies and outlook
  • The report details all the pipeline candidates under investigation in various stages of development from Phase I through to Phase III to enable business development managers to understand the impact of new launches.
  • Optimize your licensing and technology transfer strategies through identification of prospect partners
1. INTRODUCTION TO EPIDERMOLYSIS BULLOSA

1.1 Epidermolysis Bullosa- Disease overview
1.2 Epidermolysis Bullosa- Market Size
1.3 Epidermolysis Bullosa- Companies Involved

2. EPIDERMOLYSIS BULLOSA PIPELINE SNAPSHOT- 2020

2.1 Epidermolysis Bullosa Pipeline by Phase
2.2 Epidermolysis Bullosa Pipeline by Mechanism of Action
2.3 Epidermolysis Bullosa Pipeline by Route of Administration
2.4 Epidermolysis Bullosa Pipeline- New Molecular Entities
2.5 Epidermolysis Bullosa Pipeline- Orphan Drug Designation/ Special Designation

3. EPIDERMOLYSIS BULLOSA DRUG PROFILES

3.1 Current Status
3.2 Epidermolysis Bullosa Drug Snapshot
3.3 Epidermolysis Bullosa Therapeutic Candidates- Originator/Licensor
3.4 Route of Administration
3.5 Mechanism of Action
3.6 NME
4.1 Abeona Therapeutics Inc Epidermolysis Bullosa Pipeline Insights and Clinical Trials
4.2 Aegle Therapeutics Corp Epidermolysis Bullosa Pipeline Insights and Clinical Trials
4.3 Almirall SA Epidermolysis Bullosa Pipeline Insights and Clinical Trials
4.4 Amryt Pharma plc Epidermolysis Bullosa Pipeline Insights and Clinical Trials
4.5 Anterogen Co Ltd Epidermolysis Bullosa Pipeline Insights and Clinical Trials
4.6 APR Applied Pharma Research SA Epidermolysis Bullosa Pipeline Insights and Clinical Trials
4.7 Berg Pharma LLC Epidermolysis Bullosa Pipeline Insights and Clinical Trials
4.8 BridgeBio Inc Epidermolysis Bullosa Pipeline Insights and Clinical Trials
4.9 Castle Creek Biosciences Inc Epidermolysis Bullosa Pipeline Insights and Clinical Trials
4.10 Celularity Inc Epidermolysis Bullosa Pipeline Insights and Clinical Trials
4.11 Constant Pharmaceuticals LLC Epidermolysis Bullosa Pipeline Insights and Clinical Trials
4.12 CSA Biotechnologies LLC Epidermolysis Bullosa Pipeline Insights and Clinical Trials
4.13 CSL Ltd Epidermolysis Bullosa Pipeline Insights and Clinical Trials
4.14 FIBRX Derm Inc Epidermolysis Bullosa Pipeline Insights and Clinical Trials
4.15 Holostem Terapie Avanzate Srl Epidermolysis Bullosa Pipeline Insights and Clinical Trials
4.16 Immusoft Corp Epidermolysis Bullosa Pipeline Insights and Clinical Trials
4.17 InMed Pharmaceuticals Inc Epidermolysis Bullosa Pipeline Insights and Clinical Trials
4.18 Krystal Biotech Inc Epidermolysis Bullosa Pipeline Insights and Clinical Trials
4.19 LambdaGen Therapeutics Epidermolysis Bullosa Pipeline Insights and Clinical Trials
4.20 Life Sciences Institute Inc Epidermolysis Bullosa Pipeline Insights and Clinical Trials
4.21 Mesoblast Ltd Epidermolysis Bullosa Pipeline Insights and Clinical Trials
4.22 OTR3 SAS Epidermolysis Bullosa Pipeline Insights and Clinical Trials
4.23 Palvella Therapeutics LLC Epidermolysis Bullosa Pipeline Insights and Clinical Trials
4.24 Phoenix Tissue Repair Inc Epidermolysis Bullosa Pipeline Insights and Clinical Trials
4.25 Quoin Pharmaceuticals Ltd Epidermolysis Bullosa Pipeline Insights and Clinical Trials
4.26 RegeneRx Biopharmaceuticals Inc Epidermolysis Bullosa Pipeline Insights and Clinical Trials
4.27 RHEACELL GmbH & Co KG Epidermolysis Bullosa Pipeline Insights and Clinical Trials
4.28 Shionogi & Co Ltd Epidermolysis Bullosa Pipeline Insights and Clinical Trials
4.29 StemRIM Inc Epidermolysis Bullosa Pipeline Insights and Clinical Trials
4.30 Tetra Bio Pharma Epidermolysis Bullosa Pipeline Insights and Clinical Trials
4.31 TWi Biotechnology Inc Epidermolysis Bullosa Pipeline Insights and Clinical Trials
4.32 Wings Therapeutics Epidermolysis Bullosa Pipeline Insights and Clinical Trials
4.33 Zikani Therapeutics Epidermolysis Bullosa Pipeline Insights and Clinical Trials

5. EPIDERMOLYSIS BULLOSA MARKET NEWS AND UPDATES

6. APPENDIX

6.1 Sources and Methodology
6.2 Contact Information


More Publications